Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asengeprast (FT011) in Diffuse Systemic Sclerosis
NCT04647890Phase 2Completed
- Sponsor
- Certa Therapeutics
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of asengeprast in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Certa Therapeutics. Started Jul 2021; status: completed.
02
Drugs
asengeprast
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04647890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647890.